Accompanying research of Phase II study for efficacy and safety of pembrolizumab for the cytotoxic chemotherapy unfit previously untreated patients highly expressing PD-L1 positive advanced non-small cell lung cancer (1888)

Accompanying research of Phase II study for efficacy and safety of pembrolizumab for the cytotoxic chemotherapy unfit previously untreated patients highly expressing PD-L1 positive advanced non-small cell lung cancer (1888) - 1888-A

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026258

Enrollment

Registered

2017-03-27

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients enrolled onto the Phase II safety and efficacy study of nivolumab in poor performance status patients with previously untreated advanced NSCLC highly expressing PD-L1 (1888, UMIN000020855) 2) Patients providing written informed consent.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To explore the relationship between immunological state of pembrolizumab treated patients having NSCLC with poor performance status	—

Countries

Japan

Contacts

Public ContactYusuke Okuma

Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital Department of Respiratory Medicine and Thoracic Oncology

y-okuma@cick.jp03-3823-2101

Outcome results